Lucent Diagnostics announced a partnership with Life Line Screening (LLS). Through the partnership, Life Line Screening will offer Lucent's non-invasive blood based biomarker test nationally, with programs in Florida, California, and Texas already underway. This partnership supports the goals of both organizations to provide non-invasive, easily accessible testing in the general public.
According to the Alzheimer's Association, an estimated 7 million Americans are living with Alzheimer's disease today, with another 6-7 million experiencing symptoms of Mild Cognitive Impairment (MCI). These figures underscore the urgent public health need for scalable testing options that can facilitate earlier identification of the disease in its most treatable phase. Now available to their network, LLS can continue its mission by bringing cutting edge blood tests in an accessible and convenient way.
Through their mobile delivery model, LLS will provide testing opportunities in local venues such as community centers, churches, and senior centers. The results of these tests can then be shared to help primary care physicians facilitate early intervention and proactive lifestyle management for adults. Life Line Screening is a national provider operating in the 48 contiguous states.
By hosting over 15,000 community events annually, they provide a scalable infrastructure that reaches individuals in both major metropolitan areas and underserved rural regions.
